Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells $29,743.86 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 13,161 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the completion of the transaction, the insider now owns 485,701 shares in the company, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $2.24 on Friday. Ventyx Biosciences, Inc. has a 52 week low of $1.67 and a 52 week high of $11.48. The firm has a market capitalization of $158.39 million, a price-to-earnings ratio of -0.95 and a beta of 0.48. The company has a 50 day moving average price of $2.30 and a 200 day moving average price of $2.36.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Institutional Trading of Ventyx Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in Ventyx Biosciences during the second quarter valued at $32,000. Bank of New York Mellon Corp grew its stake in Ventyx Biosciences by 58.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 230,593 shares of the company’s stock valued at $533,000 after acquiring an additional 84,984 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Ventyx Biosciences by 38.0% in the 2nd quarter. Rhumbline Advisers now owns 90,331 shares of the company’s stock valued at $209,000 after purchasing an additional 24,885 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Ventyx Biosciences in the second quarter worth approximately $608,000. Finally, American Century Companies Inc. acquired a new stake in shares of Ventyx Biosciences during the second quarter worth approximately $60,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.